SCHEMBL19974846

SCHEMBL19974846

CC(NS(=O)(=O)c1ccc(F)cc1)C(=O)C(=O)NCC1CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
NPC1 O15118 1/20 0.47
HTT P42858 2/20 0.45
HPGD P15428 1/20 0.45
GFER P55789 1/20 0.45
MEN1 O00255 3/20 0.44
MMP1 P03956 2/20 0.44
MMP2 P08253 2/20 0.44
MMP3 P08254 2/20 0.44
MMP7 P09237 2/20 0.44
MMP9 P14780 2/20 0.44
MMP13 P45452 2/20 0.44
CAPN1 P07384 1/20 0.43
GAA P10253 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974713 0.89 KMT2A (0.59) KMT2AHTTHPGDMEN1ALDH1A1
SCHEMBL21176211 0.88 KMT2A (0.53) KMT2ANPC1MEN1MMP1MMP2
SCHEMBL19975409 0.88 GBA1 (0.51) KMT2AHTTHPGDMEN1ALDH1A1
SCHEMBL21176241 0.82 KMT2A (0.46) KMT2AHTTHPGDMEN1GAA
SCHEMBL19974908 0.80 KMT2A (0.52) KMT2ANPC1HTTHPGDGFER
SCHEMBL19975513 0.78 CTSL (0.50) KMT2ANPC1HPGDALDH1A1
SCHEMBL19975391 0.77 ITGAV (0.45) KMT2AHTTGAAALDH1A1SLC1A3
SCHEMBL19974751 0.77 ITGAV (0.47) KMT2AHPGDMEN1GAAALDH1A1
SCHEMBL19975110 0.76 KMT2A (0.46) KMT2AMEN1ALDH1A1SLC1A3SLC1A2
SCHEMBL27407683 0.73 CA2 (0.49) KMT2AHPGDMEN1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885NPC1 753/4885HTT 3380/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885NPC1 1213/4885HTT 3569/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885NPC1 753/4885HTT 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.